Navigation Links
Notification of Annual General Meeting and Extraordinary General Meeting
Date:6/11/2008

VALLEY COTTAGE, New York, June 11 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) today announced a notice convening its Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM"). The AGM and EGM will take place at the Conference Room at the Company's Israeli offices at Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100, at 4:00 p.m. Israel time, and 4:30 p.m. Israel time, respectively, on July 17, 2008.

At the AGM it is proposed that:

-- the annual report and financial statements for the year ended December

31, 2007 be received;

-- Kesselman & Kesselman (PricewaterhouseCoopers) be reappointed as the

Company's auditors and the fixing of their remuneration be authorized;

and

-- Messrs Michael Weiss, Ben Zion Weiner, William Kennedy, and Laurence

Charney be re-appointed as Directors of the Company.

At the EGM it is proposed that:

-- the grant of options to Michael Weiss and Ben-Zion Weiner as detailed

in the Notice be approved;

-- the grant of options to Ben-Zion Weiner and William Kennedy as detailed

in the Notice be approved; and

-- the remuneration terms for Laurence Charney as detailed in the Notice

be approved.

The Notice of the AGM and EGM is available for the public at the US Securities Exchange Edgar site: http://www.sec.gov/ and at the Israel Securities Authority's site: http://www.magna.isa.gov.il .

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (Nasdaq: XTLB; TASE: XTL).


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification (TAN) Act
2. AMICAS Transforms Critical Results Notification with RadStream
3. Merge Technologies Receives Expected Additional NASDAQ Notification
4. Memory Pharmaceuticals Receives Nasdaq Notification Related to Minimum Bid Price
5. IDM Pharma Receives Notification from NASDAQ Relating to Minimum Bid Price
6. Isolagen, Inc. Receives Notification Letter from American Stock Exchange
7. CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders Equity
8. Delisting Notification Received from the American Stock Exchange
9. PreMD Appeals American Stock Exchange Delisting Notification
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... , ... Facial plastic surgeon, Dr. John D. Rachel of Timeless You™ ... to two local organizations: North Chicago Animal Control and Friends and Our House of ... of authorized and trained volunteers who support rescued animals held in the City of ...
(Date:12/7/2016)... ... 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers Delightful ... Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 ... Delightful Deals on Botox® and Juvederm® just in time for the holiday ...
(Date:12/7/2016)... ... December 07, 2016 , ... Texas Premier Locksmith ... carried out by unethical locksmith companies and is urging Search Engines to improve ... to Texas Premier Locksmith, these fraudulent locksmith services take advantage of consumers locked ...
(Date:12/7/2016)... Dallas, TX (PRWEB) , ... December 07, 2016 ... ... a 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. ... Awards recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken ...
(Date:12/7/2016)... Studio City, CA (PRWEB) , ... December 07, 2016 , ... ... number during the holidays and winter seasons. One major study analyzing heart attacks ... January compared to August of a given year. We would all agree of course–no ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... LONDON , Dec. 6, 2016  "Blood ... all cancers announced ....." The Diagnostic, Monitoring ... revolution in cancer diagnostics is occurring using in ... a new company with impressive backing, has announced ... The technology is moving faster than the market. ...
(Date:12/6/2016)... Dec. 6, 2016 Anaplastic Oligoastrocytoma - ... Markets Direct,s latest Pharmaceutical and Healthcare disease pipeline ... provides an overview of the Anaplastic Oligoastrocytoma (Oncology) ... tumor that forms when two types of cells ... increase in number to form a mass. These ...
(Date:12/6/2016)... Eurofins Genomics today announced it has ... American Pathologists (CAP) and certification under the Clinical ... in Louisville, KY , where ... "Our new CLIA-licensed and CAP-accredited clinical ... considered the ,Gold Standard, method for validation of ...
Breaking Medicine Technology: